The goal of the BioCoStent project is to study and manufacture innovative drug-eluting coronary stents (DES) of a new generation that will overcome the disadvantages of the currently existing systems and lead to improved clinical outcomes.

BioCoStent project aims to develop an innovative coronary implant (stent) coated by retinoic acid (a metabolite of Vitamin A) in a bioabsorbable polymer.

The stent design, in the context of next generation endovascular devices, intends to overcome the disadvantages of existing systems, achieving greater biocompatibility and improved clinical results.

The use of retinoic acid for the treatment of atherosclerotic lesions involves the local intravascular administration of a completely natural, safe, and beneficial substance in contrast to the widespread use of cytotoxic drugs (e.g. Paclitaxel) which are mainly used in chemotherapy regimens.